Skip to main content

Table 1 Outcomes and effect estimates for the primary analysis|Medicaid

From: The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety

Outcomes during follow-up period

Thiazolidinedione

Pioglitazone

Rosiglitazone

N (%)

Sudden cardiac arrest/ventricular arrhythmia

295

233

 Sudden cardiac arrest

217 (73.6)

175 (75.1)

 Ventricular arrhythmia

60 (20.3)

37 (15.9)

 Both (contemporaneously)

18 (6.1)

21 (9.0)

Sudden cardiac arrest/ventricular arrhythmia immediately precededa by hospitalization for an

acute ischemic event

0 (0.0)

c

Sudden cardiac arrest/ventricular arrhythmia immediately precededa by emergency department presentation or hospitalization for hypoglycemia

c

c

Measure of sudden cardiac arrest/ventricular arrhythmia occurrence

Incidence rate (95% confidence interval)

Unadjusted, per 1000 person-years

2.67 (2.37–2.99)

3.14 (2.75–3.57)

Age- and sex-standardizedb, per 1000 person-years

2.89 (2.55–3.24)

3.38 (2.92–3.85)

Relative effect estimates for sudden cardiac arrest/ventricular arrhythmia

Hazard ratio (95% confidence interval)

Unadjusted†

1.00 (referent)

1.16 (0.98–1.38)

Confounder-adjusted‡, also see ■ in Fig. 2

1.00 (referent)

0.91 (0.75–1.10)

  1. aOperationalized as an event within the 3 days preceding hospital presentation for sudden cardiac arrest/ventricular arrhythmia
  2. bDirect standardization using age-by-sex distribution of thiazolidinedione users identified in 2005–2012 National Ambulatory Medical Care Survey (Centers for Disease Control and Prevention: Atlanta, Georgia)
  3. cOmitted in compliance with Centers for Medicare and Medicaid Services data privacy policy (i.e., prohibition of reporting cell counts < 11)
  4. †Did not fail a test for non-proportional hazards, p = 0.62
  5. ‡Did not fail a test for non-proportional hazards, p = 0.92